AlphAIAlphAI — Financial news for AI agents
stockstory.orgOCT 302 min read$FTRE

FTRE Q3 deep dive: margin gains, backlog reset, and early-phase expansion shape outlook

Fortrea Holdings (FTRE) reported Q3 2026 revenue of $691.5M, down 1.4% YoY but beating estimates. Full-year guidance was raised to $2.68B. Non-GAAP EPS of $0.28 exceeded expectations. Management cited margin gains, backlog adjustments, and early-phase expansion as key drivers. The stock price fell post-earnings.

Original reporting
stockstory.org
Published Oct 30, 2026, 4:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 31, 2026, 7:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
FTRE Q3 deep dive: margin gains, backlog reset, and early-phase expansion shape outlook — source image
Source · stockstory.org
Decision brief

The 30-second read

$FTREBullishMed
01

Why it matters

Earnings beat and raised guidance provide fresh material for short‑term trading decisions.

02

Market read

First‑report earnings with beat and guidance raise; actionable for traders evaluating CRO sector exposure.

03

What to watch

Backlog reduction of $558 M may signal weaker near‑term revenue visibility.

Relevance 8/10Novelty 8/10Timing: post‑market today

Background

Fortrea Holdings reported Q3 results, highlighted early‑phase acquisition integration and AI‑driven efficiency initiatives.

Company-level read

Ticker impact

$FTREBullishHigh confidence
Context

Q3 2026 earnings beat revenue and non‑GAAP profit expectations and raised full‑year guidance.

Expected impact

likely upward pressure as market prices in stronger guidance and margin outlook

Evidence & confidence

Beat on both top‑line and earnings, plus guidance above consensus, provides fresh material for traders.

Market effects

Sector

Positive earnings may lift the broader clinical research services sector.

Regional

U.S. biotech and pharma service providers could see modest gains.

Global

Limited to investors tracking U.S. clinical‑trial CROs.

Counterpoint

What could challenge this read

Stock fell sharply after the beat, suggesting market skepticism about margin sustainability.

Key entities

  • Company
    Fortrea Holdings

    Clinical research CRO listed on NASDAQ (FTRE).

Read at source← All news

StoryFortrea reports Q3 2026 results, raises full‑year guidance but EPS misses consensus

Also covered by

4 outlets

Related articles

OCT 30
$FTREMed

Truist raises Fortrea stock price target to $29 on margin outlook

Truist Securities raised its price target on Fortrea (NASDAQ:FTRE) to $29 from $26, maintaining a Buy rating. The stock trades at $23.14 with a $2.23B market cap. Fortrea reported a TTM book-to-bill ratio of 1.12x, below expectations, and expects Q4 adjusted EBITDA of $50M with a 7.5% margin, down from Q3. The company cited fewer working days and investments for the decline, but noted six consecutive quarters of margin upside and improving biotech demand.

investing.com2 min
OCT 30
$FTREMed

Fortrea Holdings Inc (FTRE) (Q3 2026) Earnings Call Highlights: Backlog Cleanup

Fortrea Holdings (FTRE) reported a $558M backlog adjustment, not impacting near-term revenue. Q4 EBITDA guidance was lowered due to fewer working days and IT investment. Gross margins improved from portfolio mix and efficiencies. CEO Anshul Thakral and CFO Jason Knobloch discussed growth strategies, including acquisitions like Worldwide Clinical Trials, and market recovery trends in biotech and biopharma. The company aims for mid-teens EBITDA margins and sees increasing RFP activity.

finance.yahoo.com2 min
OCT 29
$FTREHighAI 8/10

Fortrea (FTRE) Q3 2026 Earnings Call Transcript

Fortrea (FTRE) reported Q3 2026 revenue of $691.5M, adjusted EBITDA of $58M, and a book-to-bill ratio of 1.12x. The company raised full-year guidance and completed an acquisition to expand its clinical pharmacology capacity. Fortrea's strategy focuses on revenue growth and margin expansion through commercial, operational, and financial excellence.

finance.yahoo.com3 min
OCT 29
$FTREHighAI 8/10

What Fortrea (FTRE) Said on Its Q3 Earnings Call

Fortrea (FTRE) reported Q3 net income of $0.6M, up from a loss of $15.9M YoY. Adjusted net income was $27.9M, and adjusted EPS was $0.28. Operating cash flow improved to $60.8M. The company acquired Early Phase Services, expanding its clinical pharmacology network. Fortrea raised its 2026 revenue guidance to $2.665B-$2.690B and adjusted EBITDA to $210M-$218M. Management expects biotech and biopharma demand recovery.

finance.yahoo.com2 min
OCT 29
$FTREHighAI 8/10

Fortrea Q3 2026 slides: EBITDA rises 14% as revenue falls short

Fortrea Holdings (FTRE) reported Q3 2026 revenue of $691.5M, down 1.4% YoY, missing estimates by $200.83M. Adjusted EBITDA rose 14.4% to $58.0M, with margins expanding to 8.4%. EPS missed by 55.6%, and the stock fell 11% premarket. Management raised full-year guidance but warned of Q4 revenue decline. The company acquired Worldwide Clinical Trials’ Early Phase Services for $45M, improving cash flow and liquidity.

investing.com3 min